Ruminant Vaccines Market Report 2026

Ruminant Vaccines Market Overview

• Ruminant Vaccines market size has reached to $3.19 billion in 2025 • Expected to grow to $4.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Increasing Demand For Livestock Products Boosts Growth In The Ruminant Vaccine Market • Market Trend: Innovative Vaccine Shields Ruminants From Bluetongue Minimizing Disease Spread • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ruminant Vaccines Market?

Ruminant vaccines are immunizations specifically designed to protect ruminant animals from various infectious diseases. Ruminants are herbivores with a specialized stomach divided into four compartments (rumen, reticulum, omasum, and abomasum), allowing them to digest fibrous plant material. Ruminant vaccines help prevent diseases impacting ruminants' health, productivity, and welfare, such as foot-and-mouth disease, brucellosis, bovine respiratory disease, and clostridial infections. The main types of ruminant vaccines are inactivated vaccines, attenuated or modified live vaccines, and others. Inactivated vaccines are composed of pathogens that have been killed or inactivated, stimulating an immune response without causing disease, and are used to protect against various infectious diseases. They are indicated for various conditions such as bovine respiratory diseases (BRD), diarrhea or scours, foot-and-mouth disease (FMD), clostridial diseases, leptospirosis, bovine viral diarrhea (BVD) infection, and others. The vaccines are administered through intramuscular, subcutaneous, intranasal, or oral routes. These vaccines are applicable to cattle, sheep, and others. The end-users of ruminant vaccines encompass veterinary hospitals and clinics, livestock farms, and research institutes.

What Is The Ruminant Vaccines Market Growth Forecast?

The ruminant vaccines market size is expected to see strong growth in the next few years. It will grow to $4.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in vaccine technologies, increasing adoption of recombinant and mrna vaccines, growth of preventive livestock healthcare programs, rising investment in veterinary research, integration of digital vaccination monitoring systems. Major trends in the forecast period include rising demand for foot-and-mouth disease (fmd) vaccines, increasing adoption of mrna and dna-based ruminant vaccines, growth in subcutaneous and intramuscular vaccine administration, expansion of livestock vaccination programs across farms, integration of vaccination tracking systems with farm management software.

Global Ruminant Vaccines Market Segmentation

1) By Vaccine Type: Inactivated Vaccines, Attenuated Or Modified Live Vaccines, Other Vaccine Types 2) By Indication: Bovine Respiratory Diseases (BRD), Diarrhea Or Scours, Foot-and-Mouth Disease (FMD), Clostridial Diseases, Leptospirosis, Bovine Viral Diarrhea (BVD) Infection, Other Indications 3) By Route Of Administration: Intramuscular, Subcutaneous, Intranasal, Oral 4) By Application: Cattle, Sheep, Other Applications 5) By End-User: Veterinary Hospitals And Clinics, Livestock Farms, Research Institutes Subsegments: 1) By Inactivated Vaccines: Killed Virus Vaccines, Bacterial Inactivated Vaccines, Subunit Vaccines 2) By Attenuated Or Modified Live Vaccines: Live Attenuated Virus Vaccines, Live Bacterial Vaccines, Recombinant Live Vaccines 3) By Other Vaccine Types: DNA Vaccines, mRNA Vaccines, Viral Vector Vaccines

What Is The Driver Of The Ruminant Vaccines Market?

The rising demand for livestock products is expected to propel the growth of the ruminant vaccines market going forward. Livestock products are goods derived from domesticated animals, including meat, milk, eggs, wool, leather, and by-products such as gelatin and animal fats. The demand for livestock products is fueled by factors such as changing dietary preferences, increased consumer access, greater affordability, economic development, and evolving lifestyle patterns. Ruminant vaccines enhance livestock production by improving animal health, preventing disease outbreaks, increasing productivity, enhancing feed efficiency, and ensuring a stable and sustainable supply of meat, milk, and other by-products. For instance, in October 2025, according to the Department for Environment Food and Rural Affairs, a UK-based government department, in England in 2024, grazing livestock farms were the most common in lowland areas, accounting for 30% of all farms, while cereal farms occupied the largest share of agricultural land, covering 33% of the total farmed area. Therefore, the rising demand for livestock products drives the ruminant vaccines industry.

Key Players In The Global Ruminant Vaccines Market

Major companies operating in the ruminant vaccines market are Boehringer Ingelheim International GmbH, Zoetis Inc., Merck & Co. Inc., Elanco Animal Health Inc., Ceva Santé Animale, Virbac, Phibro Animal Health Corporation, Vetoquinol S.A., Indian Immunologicals Ltd., Anicon Labor GmbH (SAN Group), IDT Biologika GmbH, Jinyu Bio-Technology Co. Ltd., Vaxxinova International B.V., Biogenesis Bagó S.A, CZ Vaccines, Hester Biosciences Limited, Choong Ang Vaccine Laboratories Co. Ltd., Hipra Corporations, VETVACO National Veterinary Joint Stock Company, Kyoto Biken Laboratories Inc., Fatro Spa

Global Ruminant Vaccines Market Trends and Insights

Major companies operating in the ruminant vaccines market are focusing on developing innovative products, such as the bluetongue virus (BTV) serotype 3 vaccine, to provide effective protection against bluetongue virus serotype 3, reducing mortality, clinical signs, and virus transmission in livestock. The bluetongue virus (BTV) Serotype 3 vaccine is a preventive immunization used to protect ruminants, such as cattle and sheep, from bluetongue disease caused by serotype 3 of the bluetongue virus. For instance, in May 2024, Boehringer Ingelheim International GmbH, a Germany-based biopharmaceutical company, launched Bultavo 3 to its ruminant vaccine portfolio. This vaccine is inactivated and offers protection against bluetongue virus serotype 3, significantly reducing virus circulation in the blood and preventing both mortality and clinical signs. Its introduction addresses the urgent need for a BTV-3 vaccine due to recent outbreaks, helping to mitigate the impact on livestock health and reducing economic losses for farmers.

What Are Latest Mergers And Acquisitions In The Ruminant Vaccines Market?

In April 2024, Virbac Group, a France-based company that manufactures animal health products, acquired Sasaeah Pharmaceutical Co. Ltd. for an undisclosed amount. This acquisition aims to enhance Virbac's leadership position in the Japanese livestock vaccine market, particularly for cattle, by leveraging Sasaeah's established production facilities, extensive research and development capabilities, and broad pharmaceutical portfolio to support its strategic growth and expand its footprint in animal health. Sasaeah Pharmaceutical Co. Ltd. is a Japan-based company that manufactures ruminant vaccines.

Regional Outlook

North America was the largest region in the ruminant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Ruminant Vaccines Market?

The ruminant vaccines market consists of sales of brucellosis vaccines, bluetongue virus vaccines, E. coli vaccines, mycoplasma vaccines, and chlamydia vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.